Smart drugs target prostate tumours
Prostate cancer is entering the era of 'precision medicine', bringing a new approach and a new class of highly-focused drugs that have begun helping men with a particular genetic defect.
The DDR genetic defect occurs in 10-12 per cent of men with lethal prostate cancer. Westend61
A new form of treatment is emerging for prostate cancer. Rather than the traditional “one-size fits all” approach developed for the average man; this new approach is tailored to the individual man.
Using sophisticated technology and smart drugs, it targets the particular genetic make-up of his prostate tumour.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Health & wellness
Fetching latest articles